Earnings summaries and quarterly performance for Spero Therapeutics.
Executive leadership at Spero Therapeutics.
Board of directors at Spero Therapeutics.
Research analysts who have asked questions during Spero Therapeutics earnings calls.
Ritu Baral
TD Cowen
2 questions for SPRO
Also covers: ACAD, ALNY, ATAI +11 more
Gautam Chukka
Evercore ISI
1 question for SPRO
Gavin Clark-Gartner
Evercore ISI
1 question for SPRO
Also covers: ACRS, ARGX, ASND +11 more
Louise Chen
Cantor Fitzgerald
1 question for SPRO
Also covers: ARDX, CNTB, IMAB +14 more
Ram Selvaraju
H.C. Wainwright
1 question for SPRO
Also covers: ABEO, ADXN, BCPC +8 more
Recent press releases and 8-K filings for SPRO.
Spero Therapeutics Announces Q3 2025 Results and Tebipenem HBr FDA Filing Plans
SPRO
Earnings
Guidance Update
New Projects/Investments
- Spero Therapeutics reported a net loss of $7.4 million and total revenue of $5.4 million for the third quarter ended September 30, 2025.
- The company's development partner, GSK, plans to submit data from the Phase 3 PIVOT-PO trial for tebipenem HBr to the US FDA in Q4 2025, with a regulatory decision anticipated in 2H 2026. The trial demonstrated non-inferiority of tebipenem HBr compared to intravenous imipenem-cilastatin for complicated urinary tract infection (cUTI), with an overall success rate of 58.5%.
- Spero Therapeutics has discontinued the SPR720 program in Q3 2025 following a review of Phase 2a and Phase 1 trial data.
- As of September 30, 2025, Spero had $48.6 million in cash and cash equivalents, which is expected to fund operations into 2028.
Nov 13, 2025, 10:18 PM
Spyre Therapeutics Announces Closing of Public Offering
SPRO
New Projects/Investments
- Spyre Therapeutics, Inc. announced the closing of its underwritten public offering, which included the full exercise of the underwriters’ option to purchase additional shares.
- The offering comprised 17,094,594 shares of common stock at a public offering price of $18.50 per share.
- The gross proceeds generated from the offering totaled approximately $316.2 million.
Oct 15, 2025, 8:15 PM
Quarterly earnings call transcripts for Spero Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more